These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
676 related articles for article (PubMed ID: 20459769)
1. Antitumor and antiangiogenic effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. Diaz R; Nguewa PA; Parrondo R; Perez-Stable C; Manrique I; Redrado M; Catena R; Collantes M; Peñuelas I; Díaz-González JA; Calvo A BMC Cancer; 2010 May; 10():188. PubMed ID: 20459769 [TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models. Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856 [TBL] [Abstract][Full Text] [Related]
3. The HDAC inhibitor, MPT0E028, enhances erlotinib-induced cell death in EGFR-TKI-resistant NSCLC cells. Chen MC; Chen CH; Wang JC; Tsai AC; Liou JP; Pan SL; Teng CM Cell Death Dis; 2013 Sep; 4(9):e810. PubMed ID: 24052078 [TBL] [Abstract][Full Text] [Related]
4. Anti-tumor activity of high-dose EGFR tyrosine kinase inhibitor and sequential docetaxel in wild type EGFR non-small cell lung cancer cell nude mouse xenografts. Tang N; Zhang Q; Fang S; Han X; Wang Z Oncotarget; 2017 Feb; 8(6):9134-9143. PubMed ID: 27852073 [TBL] [Abstract][Full Text] [Related]
5. Lymecycline reverses acquired EGFR-TKI resistance in non-small-cell lung cancer by targeting GRB2. Chen Y; Wu J; Yan H; Cheng Y; Wang Y; Yang Y; Deng M; Che X; Hou K; Qu X; Zou D; Liu Y; Zhang Y; Hu X Pharmacol Res; 2020 Sep; 159():105007. PubMed ID: 32561477 [TBL] [Abstract][Full Text] [Related]
6. Cyclosporine A sensitizes human non-small cell lung cancer cells to gefitinib through inhibition of STAT3. Shou J; You L; Yao J; Xie J; Jing J; Jing Z; Jiang L; Sui X; Pan H; Han W Cancer Lett; 2016 Aug; 379(1):124-33. PubMed ID: 27264264 [TBL] [Abstract][Full Text] [Related]
7. Lapatinib, a Dual Inhibitor of Epidermal Growth Factor Receptor (EGFR) and HER-2, Enhances Radiosensitivity in Mouse Bladder Tumor Line-2 (MBT-2) Cells In Vitro and In Vivo. Mu Y; Sun D Med Sci Monit; 2018 Aug; 24():5811-5819. PubMed ID: 30125265 [TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236 [TBL] [Abstract][Full Text] [Related]
9. Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR. Li J; Deng H; Hu M; Fang Y; Vaughn A; Cai X; Xu L; Wan W; Li Z; Chen S; Yang X; Wu S; Xiao J Oncotarget; 2015 Mar; 6(9):6749-61. PubMed ID: 25730907 [TBL] [Abstract][Full Text] [Related]
10. Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance. Cretella D; Saccani F; Quaini F; Frati C; Lagrasta C; Bonelli M; Caffarra C; Cavazzoni A; Fumarola C; Galetti M; La Monica S; Ampollini L; Tiseo M; Ardizzoni A; Petronini PG; Alfieri RR Mol Cancer; 2014 Jun; 13():143. PubMed ID: 24898067 [TBL] [Abstract][Full Text] [Related]
11. The synergistic effect of EGFR tyrosine kinase inhibitor gefitinib in combination with aromatase inhibitor anastrozole in non-small cell lung cancer cell lines. Shen L; Li Z; Shen S; Niu X; Yu Y; Li Z; Liao M; Chen Z; Lu S Lung Cancer; 2012 Dec; 78(3):193-200. PubMed ID: 22985911 [TBL] [Abstract][Full Text] [Related]
12. Combined therapy with mutant-selective EGFR inhibitor and Met kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant lung cancer. Nakagawa T; Takeuchi S; Yamada T; Nanjo S; Ishikawa D; Sano T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Sekido Y; Uenaka T; Yano S Mol Cancer Ther; 2012 Oct; 11(10):2149-57. PubMed ID: 22844075 [TBL] [Abstract][Full Text] [Related]
13. Anti-invasion, anti-proliferation and anoikis-sensitization activities of lapatinib in nasopharyngeal carcinoma cells. Lui VW; Lau CP; Ho K; Ng MH; Cheng SH; Tsao SW; Tsang CM; Lei KI; Chan AT; Mok TS Invest New Drugs; 2011 Dec; 29(6):1241-52. PubMed ID: 20571878 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance. Morrison G; Fu X; Shea M; Nanda S; Giuliano M; Wang T; Klinowska T; Osborne CK; Rimawi MF; Schiff R Breast Cancer Res Treat; 2014 Apr; 144(2):263-72. PubMed ID: 24554387 [TBL] [Abstract][Full Text] [Related]
15. Clathrin-mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild-type EGFR non-small cell lung cancer. Kim B; Park YS; Sung JS; Lee JW; Lee SB; Kim YH Cancer Med; 2021 Jan; 10(1):372-385. PubMed ID: 33314735 [TBL] [Abstract][Full Text] [Related]
16. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Xie M; He CS; Wei SH; Zhang L Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913 [TBL] [Abstract][Full Text] [Related]
17. The autophagy inhibitor chloroquine overcomes the innate resistance of wild-type EGFR non-small-cell lung cancer cells to erlotinib. Zou Y; Ling YH; Sironi J; Schwartz EL; Perez-Soler R; Piperdi B J Thorac Oncol; 2013 Jun; 8(6):693-702. PubMed ID: 23575415 [TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels. Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836 [TBL] [Abstract][Full Text] [Related]
19. Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines. Collins DM; Crown J; O'Donovan N; Devery A; O'Sullivan F; O'Driscoll L; Clynes M; O'Connor R Invest New Drugs; 2010 Aug; 28(4):433-44. PubMed ID: 19499189 [TBL] [Abstract][Full Text] [Related]
20. Lapatinib, a dual inhibitor of EGFR and HER2, has synergistic effects with 5-fluorouracil on esophageal carcinoma. Guo XF; Zhu XF; Zhong GS; Deng BG; Gao ZT; Wang H Oncol Rep; 2012 May; 27(5):1639-45. PubMed ID: 22293713 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]